Jump to Main Content
- Qin Lingyun, et al. Show all 7 Authors
- Biochemistry 2017 v.56 no.25 pp. 3273-3282
- amino acids; antineoplastic activity; drugs; fluorescence; fluorescence emission spectroscopy; ligands; models; neoplasms; oncogene proteins; screening; therapeutics
- ... In nearly half of cancers, the anticancer activity of p53 protein is often impaired by the overexpressed oncoprotein Mdm2 and its homologue, MdmX, demanding efficient therapeutics to disrupt the aberrant p53–MdmX/Mdm2 interactions to restore the p53 activity. While many potent Mdm2-specific inhibitors have already undergone clinical investigations, searching for MdmX-specific inhibitors has become ...